)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Ascendis Pharma
Ascendis Pharma (ASND) investor relations material
Ascendis Pharma 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Key business and financial highlights
Entered 2026 with strong financial footing, reporting $1.86 billion in 2025 net product revenue and $954 million in cash.
Elevidys generated $899 million in 2025, with 9% growth, and PMOs contributed $966 million, remaining flat despite some cannibalization.
Maintains a $500 million annual revenue floor for Elevidys, with plans to significantly exceed it in 2026.
Restructured convertible debt, resulting in no significant debt overhang for the decade and anticipated continued profitability and cash flow positivity.
Stress tests indicate the company can meet debt obligations even under adverse scenarios.
Strategic vision and growth targets
Aims to achieve over €5B annual revenue by 2030, focusing on blockbuster status for multiple products and expanding innovation in endocrinology rare diseases and other therapeutic areas.
Plans to remain independent and profitable through lean operations and a strong innovation algorithm.
Pursues accelerated oncology approvals and partnerships to maximize value in large indications.
Commercial and product strategy
Focused on expanding Elevidys uptake, with 80% of the ambulatory population still untreated and a robust plan to communicate efficacy data.
Increased sales force and launched a new promotional campaign to support Elevidys growth.
Pathway to non-ambulatory patient treatment depends on success of ENDEAVOR Cohort 8, with results expected at year-end.
YORVIPATH approved for adult hypoparathyroidism, with commercial launches in 30+ countries and expansion planned by end of 2026.
SKYTROFA approved for pediatric and adult growth hormone deficiency, with label expansions and global rollout ongoing.
How does COACH data impact ACH market strategy
YORVIPATH US penetration strategy beyond 5%
Impact of TransCon CNP on 2026 cash flow outlook
How will Ascendis achieve EUR 5B+ revenue by 2030?
YORVIPATH U.S. growth drivers for 2026?
TransCon CNP combination: What are its key benefits?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ascendis Pharma earnings date
Q4 202511 Feb, 2026
Ascendis Pharma
Next Ascendis Pharma earnings date
Q4 202511 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ascendis Pharma A/S is a biopharmaceutical company leveraging its TransCon technology platform to develop treatments for patients with unmet medical needs in endocrinology and oncology. The company's proprietary TransCon technology is designed to enhance the efficacy, safety, and administration of existing molecules, resulting in new therapies that could potentially offer best-in-class benefits. Ascendis Pharma's approach combines the benefits of prodrug and sustained-release technologies, enabling the controlled release of active pharmaceutical ingredients. The company is headquartered in Copenhagen, Denmark, and its shares are listed on the NASDAQ under the ticker symbol ASND.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage